Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Your boss IP is from UK. What's yours? From the post I read before, you are in Georgia. Right?
I have enough exchange with you now. You are a lightweight. Not worthy of my time. Give back the account to your hypocrite billionaire boss.
My bad, misfire then.
Think about what happened when the preprint was out. If you were an institutional investor and you happened to read the paper, would you throw big money right away? The answer is no. You would read it and you would call experts to collect their opinions and you would have several rounds of meetings and discussions. You may reach LP directly to see if you can load more shares in a cheap way. Is it supposed to be this procedure?
Just so you know. I have no interest in you. Your boss, that hypocrite billionaire is the one I am interested. You can rat him out and come to Laura as a whistle blower if you want to get rich fast.
So now you know that it is possible NWBO longs may give credit to my posts. I am certain every NWBO long will pay no attention to your BS.
Everyone needs to read it and digest it first. I know for a fact you never read it even though the preprint has been there since last August. That's why you are on the wrong side of the history.
Every month, nine million people read news, analysis and commentary on nature.com. We are committed to developing the next generation of scientists through our backing for the Nature Awards for Mentoring in Science, the John Maddox Prize for Standing up for Science and the Nature Research Awards for Inspiring and Innovating Science.
Stupid minion. Never learned a thing. Change your user name.
Thank you, Dude. I should buy you beer if by any chance I meet you.
I need to expose who you are. But more importantly, I want LP, Coffer Black, and Laura Posner to take a look too. Have you asked yourself how Laura Posner could download 235,194 posts? She must have the court order. Along with these posts are the IP address. Your boss has IP address from UK. Ask yourself what is your IP address. You can ask Ex who knows better in this regard.
You guys as shareholders have done a wonderful job. It's amazing what you guys find and how fast you [indiscernible]. I have said that I think the [indiscernible] should lay off all their employees and just contact with you guys because you find everything faster than anybody. But in all seriousness, is serious. We try to strike a balance between taking action, but not diverting too many of those precious hours from working on the applications for approval because that's what the attackers want. They want our time, attention and resources to be diverted and taken away from making progress.
To measure investor enthusiasm, Plaintiff downloaded all 235,194 posts during the Relevant Period on the NWBO message board on InvestorsHub, and applied standard sentiment analysis, which scores the message board post according to standard methods employed in the peer-reviewed literature.
NWBO longs,
Send anything that you think Laura Posner might have interest investigating further.
Laura H. Posner
Michael B. Eisenkraft
COHEN MILSTEIN SELLERS & TOLL PLLC
88 Pine Street, 14th Floor
New York, New York 10005
Tel: (212) 838-7797
Fax: (212) 838-7745
lposner@cohenmilstein.com
meisenkraft@cohenmilstein.com
Raymond M. Sarola (RS1010)
Cohen Milstein Sellers & Toll PLLC
100-120 N. 18th Street, Suite 1820
Philadelphia, PA 19103
Tel: (267) 479-5700
Fax: (267) 479-5701
rsarola@cohenmilstein.com
He most likely got the medical record from someone else. I really question if he did it with the patient's consent. Laura Posner can find out.
Bravo!! bio, you nailed him.
He used to think of himself as the largest retailer of NWBO. But it seems like suppressing NWBO can make him more than holding it.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157574329
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165281637
Just a reminder, your boss likes using the word "mate" a lot.
Now he hires a low-level minion to handle his account.
Just wonder if this presentation is related to the case study paper mentioned by NWBO and accepted for publication.
Tumour Regression Following DCVax-L Immunotherapy: An Illustrated Case Report
https://www.sbns.org.uk/index.php/download_file/view/2338
Dude,
Great post!
Radio silence means NWBO is preparing for big war.
What did Warren Buffet say?
'The most important thing to do if you find yourself in a hole is to stop digging.'
Have you checked out all the papers from Dr. Liau which have all the data uploaded to GEO DataSets? Obviously, you haven't.
Here is the link of all the papers. Go through each of them before you roll the dice and post nonsense.
https://www.ncbi.nlm.nih.gov/gds/?term=Liau%20LM
Fabulous post! Agree with you totally about the following.
Since 2014, poly-ICLC has been referred to as a component in the DCVax-L formulation, and not as an adjuvant treatment. Poly-ICLC was only referred to as an adjuvant treatment in the original 2010 trial.
In all of the current and future combination trials, including the current Pembrolizumab combination trial, and the future planned Pembrolizumab + CSF-1R combination trial, poly-ICLC is not mentioned or depicted separately from DCVax-L, but is included with DCVax-L as a component:
I feel like the acquisition deal of Prometheus by Merck may give us some rough estimate on the value of NWBO.
The size UC and CD market is about $23b in 2022 and Merck spent about half of $23b on BO. Note that Prometheus didn't have phase 3 trial. The solid tumor market is between $200b and $300b I suspect. The value of NWBO should be a big number.
https://s21.q4cdn.com/488056881/files/doc_presentations/2023/04/Splash-Investor-Event-Slides-FINAL-1.pdf
I only found there was a change on date.
https://classic.clinicaltrials.gov/ct2/history/NCT04201873?A=8&B=9&C=Side-by-Side#StudyPageTop
Has anyone noticed there was an update on the combo trial?
https://clinicaltrials.gov/study/NCT04201873?cond=atl-dc&rank=1
I can guarantee you this is not my last response to you. But you haven't been honest with the simple fact that you are whosleftholdindabag, a billionaire holding NVCR.
Mate, you are so obnoxious. You haven't realized that you reek. You are not a NWBO investor. You come on this board impersonating as military man, government inspector, GBM patients, CHM attendee with sole purpose to deceive the retailers. You think you are going to run away with all these nonsense? How much money have you ripped off from the NWBO shareholders? That's something we all want to find out.
Does your wife and children know what you are doing? You strike me as another Bernie Madoff.
Read your posts again to see if these posts can jog your memory.
You don't? Search ihub to see if there is anyone else who uses the word "mate" frequently.
I just need to make sure that you are the one who has the GBM.
I could be a basement dweller. But who are you? Are you that billionaire who hire all these minions to bash a company which is trying to treat cancer?
BTW, when are you going to sue me? Please do. I want so badly to have full disclosure of both of us to the world.
You attended the CHM and shared your testimony. Did I get that right?
Great.
You are rich enough to afford private doctors. You don't mind I double check with the two doctors to verify if you are telling the truth, do you?
https://kingsprivate.com/consultant/dr-istvan-bodi/
https://kingsprivate.com/consultant/mr-ranj-bhangoo/
Wow, you know a lot about this stuff. Now tell me who did the server attack on virtualtrials.org on May 10.
BTW the dark forces issue you check or pay you cash?
And you do know even in UK impersonating a government officer with the intent to deceive is considered a crime?
I am only concerned about your intent.
Senior Global Study Manager – Cell Therapy, Oncology R&D, Early Clinical
locations Gaithersburg, Maryland, United States Waltham, Massachusetts, United States South San Francisco, California, United States https://careers.astrazeneca.com/job/gaithersburg/senior-global-study-manager-cell-therapy-oncology-r-and-d-early-clinical/7684/64469951424
The Senior Global Study Manager, Cell Therapy is responsible for leading the operational activities to support and enable the delivery of cell therapy clinical studies ensuring quality and compliance. The exact accountabilities will differ depending on the nature of the clinical program or clinical study, so a high degree of flexibility is required.
Typical Accountabilities
Provide operational expertise to the Study Team.
Lead the development of study documents as well as any updates/amendments, ensuring template and version compliance.
Lead the preparation of country specific agreements, confidentiality agreements, clinical trial applications and other applicable country documents.
Provide mentoring and guidance to the operations team ensuring effective collaboration and communication with the Study Team.
Manage the set-up of third-party vendors, assessing initial statement of work and budget, as well as the change order process.
Provide input to data management documents and interface with data management representatives and sites to facilitate the delivery of study data.
Initiate contract/budget requests and track ongoing status; facilitate generation of purchase orders, review vendor invoices and assist in tracking spend against approved budget.
Ensure the supply of study materials and ensure the appropriate allocation of apheresis/manufacturing slot availability by liaising with Cell Therapy Operations (CTO) or external service providers as appropriate.
Oversight of third-party vendors, global / local internal staff, and investigator sites to support effective delivery of a study and its regulatory documents.
Provide oversight of and support recruitment and data delivery as well as risk mitigation strategies.
Oversee the clinical trial insurance process, track approvals, revisions, and renewals of certificates.
Monitor study conduct and progress, proactively identifying and resolving issues which may impact delivery of the study to the necessary quality, timelines, or budget.
Drive risk management and quality efforts to ensure study compliance.
Manage set-up, maintenance, closeout and archiving of the Trial Master File (TMF), ensuring continual inspection readiness.
Prepare presentation material for meetings, newsletters, and websites.
Direct the Study Team in the implementation of audits and regulatory inspections.
Identify areas of best practice / process improvements and knowledge share across the Cell Therapy Clinical Group.
Contribute to review of new/amended/unique SOPs and guidance documents.
Education, Qualifications, Skills, and Experience
Essential
Bachelor’s Degree and 5+ years of experience, Associate’s degree plus 9+ years of experience or High School plus 13+ years of experience, of which at least 2 years are in global study management.
Experience of working with and delivering through strategic partners and 3rd party vendor
Excellent knowledge of ICH-GCP principles.
Team orientated.
Ability to lead, coordinate and prioritise multiple tasks and deliverables.
Proactive approach to achieving study goals.
Demonstrated verbal and written communication skills.
Good negotiation and collaboration skills.
Demonstrated interpersonal and problem- solving skills.
Ability to manage change and actively seek and champion more efficient and effective ways of working.
Ability to coach & act as a buddy for more junior colleagues.
Some travel may be required.
Desirable
Early phase oncology clinical trial experience.
Experience in autologous or allogeneic oncology therapies
I would like to borrow the last two words from Perk_Idaho's post and throw at you.
Mate,
On one hand, you claim all your proceeds from NVCR will go to charity; on the other hand, you are trying to bankrupt a company that will deliver the much-needed treatment to one of the most life-threatening cancer. Do you have dissociative identity disorder? Seems like you need to worry about your own mental health. Take a look at the following statistics. How could you sleep at night?
The genomic background of pediatric tumors is different from that of adult tumors. The same tumor types tend to have completely different mutation profiles compared to their adult counterparts. Statistics have revealed that in children, solid tumors make up about 40% of all cancers. The most common and aggressive type of solid tumor found in children is a brain tumor.
The commentary within has zero impact on any outcome of significance.
Is It Illegal to Impersonate a Federal Agent?
Pretending to be a federal agent is a federal crime in the United States, punishable under 18 U.S.C. § 912.
It is a crime to falsely represent oneself as a federal agent or employee with the intent to intimidate or deceive another person.
This offense carries a maximum penalty of three years in prison and a fine.
Additionally, state laws may also prohibit impersonating a law enforcement officer.
It is important to note that it is illegal to impersonate a federal agent, regardless of whether the person being impersonated is real or fictional.
I can give credit to what you said. But first you have to confirm that you are the one who said the following.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174095255
As a former Soldier, and absolute Royalist, it is beyond utter contempt, that you view Our Princess Catherine’s cancer diagnosis, as, maybe, an opportunity to promote the effectiveness of DCVAX, so you all can get your parasitic, sweaty grubby hands on a few desperately needed investment dollars.
As someone who was an Inspector for a Government Regulatory Authority for over a Decade, if there are any concerns raised, as to the veracity of the presented ‘paperwork’, typically, well I certainly would have, gone right back to the very beginning of the paper trail.
biosectinvestor,
I went through all the trials on cancer SWOG was running. It seems like that SWOG is playing with various combinations of the different drugs from all the BPs. I haven't seen any extraordinary results from any of these trials. I am really curious about the objectives of these trials. Is SWOG trying to find some combinations that are really working? It seems like SWOG is trying to convince people that none of these combinations are working.
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)
https://classic.clinicaltrials.gov/ct2/show/NCT04071457?recrs=ab&lead=swog&draw=2&rank=26
Daratumumab -- Janssen Biotech, Inc.
Lenalidomide -- Bristol Myers Squibb
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
https://classic.clinicaltrials.gov/ct2/show/NCT04205968?recrs=ab&lead=swog&draw=2&rank=24
Paclitaxel -- Bristol-Myers Squibb
Ramucirumab -- Eli Lilly
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial (PROBE)
https://classic.clinicaltrials.gov/ct2/show/NCT04510597?recrs=ab&lead=swog&draw=2&rank=21
Nivolumab -- Bristol-Myers Squibb
Pembrolizumab -- Merck
Avelumab -- Merck KGaA and Pfizer
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
https://classic.clinicaltrials.gov/ct2/show/NCT04511013?recrs=ab&lead=swog&draw=2&rank=20
Binimetinib -- Pfizer
Encorafenib -- Pfizer
Ipilimumab -- Bristol-Myers Squibb
Nivolumab -- Bristol-Myers Squibb
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT04625647?recrs=ab&lead=swog&draw=2&rank=19
Sotorasib -- Amgen
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
https://classic.clinicaltrials.gov/ct2/show/NCT04647916?recrs=ab&lead=swog&draw=2&rank=18
Sacituzumab Govitecan -- Gilead
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
https://classic.clinicaltrials.gov/ct2/show/NCT05040360?recrs=ab&lead=swog&draw=2&rank=15
Capecitabine -- Roche
Temozolomide -- Merck
Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer
https://classic.clinicaltrials.gov/ct2/show/NCT05364645?recrs=ab&lead=swog&draw=2&rank=14
Pemetrexed -- Eli Lilly
Selpercatinib -- Eli Lilly
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
https://classic.clinicaltrials.gov/ct2/show/NCT05561387?recrs=ab&lead=swog&draw=2&rank=12
Bortezomib -- Takeda
Daratumumab and Hyaluronidase-fihj -- Johnson & Johnson
Lenalidomide -- Bristol-Myers Squibb
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
https://classic.clinicaltrials.gov/ct2/show/NCT05633602?recrs=ab&lead=swog&draw=2&rank=10
Pembrolizumab -- Merck
Ramucirumab -- Eli Lilly
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
https://classic.clinicaltrials.gov/ct2/show/NCT05633615?recrs=ab&lead=swog&draw=2&rank=9
Axicabtagene Ciloleucel -- Gilead
Lisocabtagene Maraleucel -- Bristol-Myers Squibb
Tisagenlecleucel -- Novartis
Polatuzumab Vedotin -- Roche
Mosunetuzumab -- Roche
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT05642572?recrs=ab&lead=swog&draw=2&rank=8
Capmatinib -- Novartis
Osimertinib -- AstraZeneca
Ramucirumab -- Eli Lilly
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
https://classic.clinicaltrials.gov/ct2/show/NCT05806515?recrs=ab&lead=swog&draw=2&rank=6
Carboplatin -- Bristol-Myers Squibb
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
https://classic.clinicaltrials.gov/ct2/show/NCT05890352?recrs=ab&lead=swog&draw=2&rank=5
Lenalidomide -- Bristol-Myers Squibb
Tafasitamab -- Incyte
Tazemetostat -- Ipsen
Zanubrutinib -- BeiGene
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
https://classic.clinicaltrials.gov/ct2/show/NCT05929768?recrs=ab&lead=swog&draw=2&rank=4
Carboplatin -- Bristol-Myers Squibb
Paclitaxel -- Bristol-Myers Squibb
Pembrolizumab -- Merck
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT06031688?recrs=ab&lead=swog&draw=2&rank=2
Ramucirumab -- Eli Lilly
Tepotinib -- Merck KGaA
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT06116682?recrs=ab&lead=swog&draw=2&rank=1
Amivantamab -- Janssen and Genmab
Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT04268550?recrs=bd&lead=swog&draw=2&rank=6
Selpercatinib -- Eli Lilly
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT05096663?recrs=bd&lead=swog&draw=2&rank=4
Nogapendekin Alfa -- ImmunityBio
Pembrolizumab -- Merck
Ramucirumab -- Eli Lilly
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT06116682?recrs=bd&lead=swog&draw=2&rank=1
Amivantamab -- Janssen and Genmab
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT06031688?recrs=bd&lead=swog&draw=2&rank=2
Ramucirumab -- Eli Lilly
Tepotinib -- Merck KGaA
So RevImmune solely owned by LP would prefer to use other DC vaccines while LP knew very well about the efficacy of DCVax-L. Do you have other smart ways to counter my point?